White blood cell count profiles in multiple sclerosis during attacks before the initiation of acute and chronic treatments

Abstract Multiple sclerosis (MS) is a major demyelinating disease of the central nervous system; however, its exact mechanism is unknown. This study aimed to elucidate the profile of white blood cells (WBCs) in the acute phase of an MS attack. Sixty-four patients with MS at the time of diagnosis and...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Tetsuya Akaishi, Tatsuro Misu, Kazuo Fujihara, Naoki Nakaya, Tomohiro Nakamura, Mana Kogure, Rieko Hatanaka, Fumi Itabashi, Ikumi Kanno, Toshiyuki Takahashi, Hiroshi Kuroda, Juichi Fujimori, Yoshiki Takai, Shuhei Nishiyama, Kimihiko Kaneko, Tadashi Ishii, Masashi Aoki, Ichiro Nakashima, Atsushi Hozawa
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2021
Materias:
R
Q
Acceso en línea:https://doaj.org/article/dfa9aee74d564861b2f98ebcbdf9c0b3
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
Descripción
Sumario:Abstract Multiple sclerosis (MS) is a major demyelinating disease of the central nervous system; however, its exact mechanism is unknown. This study aimed to elucidate the profile of white blood cells (WBCs) in the acute phase of an MS attack. Sixty-four patients with MS at the time of diagnosis and 2492 age- and sex-adjusted healthy controls (HCs) were enrolled. Data regarding the blood cell counts were compared between the groups. The total WBC (p < 0.0001), monocyte (p < 0.0001), basophil (p = 0.0027), and neutrophil (p < 0.0001) counts were higher in the MS group than in the HC group, whereas the lymphocyte and eosinophil counts did not differ. Adjustments for the smoking status and body mass index yielded the same results. The total and differential WBC counts of the patients with MS did not correlate with the counts of T2 hyperintense brain lesions or the levels of neurological disturbance. In summary, patients with MS showed elevated counts of total WBCs, monocytes, basophils, and neutrophils at the time of diagnosis. However, the clinical relevance of these biomarkers in the context of the development and progression of MS remains unclear.